Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of Care Management Options Consultancy Ltd, known as Face 2 Face (“Face 2 Face”). Financial details of the deal were not disclosed.
Geneva, Switzerland - AMAL Therapeutics SA (AMAL), a Swiss biotech developing peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF 33.2 million). AMAL received follow-on funding from the same syndicate of investors that committed €8 million at the first close in September 2017.
Naarden, The Netherlands - NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the publication of two posters to be presented at the AASLD The Liver MeetingTM 2018 in San Francisco on 9-13 November. The posters will outline the Company’s latest research data of its lead product’s anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces positive data from the first two elements of its human study which focus on skin irritancy and moisturisation potential.
Buffalo Grove, IL, and Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has launched Vancomycin Hydrochloride for Injection, USP within the United States market.
Paris, France – Taking on board learnings from challenges already faced and focusing on advanced, longer-term studies of variables within microbiome research will be key to fostering confidence and integration between experts working in the microbiome and those working in pure therapeutics says a new report written by Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement. Takeda has taken an exclusive licence to Humabodies directed to one of its oncology targets.
Cambridge, UK, – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel.
London, UK and Carlsbad, CA, USA – A rapid new diagnostic platform that harnesses the power of semiconductor DNA sequencing, promises to revolutionise the ability of physicians to treat antimicrobial resistant infections.
Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the business and assets of Atlantic Support (Devon) Ltd (“Atlantic”), purchased by NCG’s subsidiary Atlantic Way Care Ltd. Financial details of the deal were not disclosed.
Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).
Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, today announces that it has led a €17m Series C financing of OMEICOS Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin, Germany.
Cambridge, UK – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced that it will present preclinical data on two new proprietary bispecific antibodies at the SITC Annual Meeting, PEGS Summit Europe and the ESMO Immuno-Oncology Congress.
London, UK and Melbourne, Australia – BioScience Managers Limited (BioScience Managers), the international healthcare investment firm today announces the appointment of Dr. Kate Rowley as Investment Director, based in London. Reflecting BioScience Managers’ international focus Dr. Rowley’s role will be to review and evaluate healthcare investment opportunities and manage investment deals from across the globe, in particular from the UK and Europe.
Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November.
Munich, Germany – EBD Group (‘EBD’), the market-leading provider of world-class partnering events and tools for the global life science industry, has opened its newly updated partneringONE® platform for BIO-Europe® 2018, Europe's largest life science partnering conference, following a successful trial at the recent BioPharm America™ conference.
Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it will be represented at the World Anti-Microbial Resistance Congress in Washington D.C., 25 - 26 October 2018.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2018.
Cambridge, Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that it has conditionally raised a total of £1.375 million (before expenses) via a proposed placing, by Peterhouse Capital Limited, and subscription of a total of 91,666,666 new ordinary shares (“New Ordinary Shares”), at an issue price of 1.5 pence per New Ordinary Share (the “Issue Price”).
Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.
Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m.
Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, today announced a key partnership with the UK’s Epilepsy Society to study the genomics of sudden unexpected death in epilepsy (SUDEP). The new collaboration, announced on SUDEP Action Day, aims to improve the clinical understanding, prediction and treatment of the devastating and unpredictable condition, which affects approximately 1 in 1,000 adult and 1 in 4,500 paediatric patients with epilepsy every year.
Cambridge: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company, Feedback Medical Ltd, has received a number of substantial orders for TexRAD®, its patented image texture analysis technology, from prestigious university hospitals across Europe.
Groningen, The Netherlands – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage following brain surgery.